Amplat Inc. is pleased to announce that it has begun a collaboration with Digzyme Inc.
As part of this initiative, in collaboration with digzyme Inc., a group of experts in enzyme discovery and improvement, Amprat has announced the launch of “digzyme in silico DMS (Deep Mutational Scanning),” an analysis service on its data analysis technology sharing platform, “ANCAT,” which predicts with high accuracy the activity of enzyme mutants and the function of single mutants of enzymes for precision fermentation and in vitro diagnostics.
Enzymes are substances that make our lives more comfortable, such as softening tough meat and increasing the cleaning effect of detergents. They can be said to be the most familiar product of life science research that is put into society. However, enzyme research is very difficult and time-consuming. In fact, many of the enzymes currently in practical use were discovered by chance during the research process, and to put it bluntly, the current situation is that we have no choice but to wait for coincidences.
Also Read: Nuclera Expand Distribution Across APAC and Middle East
Enzymes are a type of protein that consists of a string of about 100-1000 amino acids of 20 different kinds, but artificially creating mutants (amino acid substitutions) is a laborious task. When considering each mutation and its combination, there are a huge number of candidates, and highly specialized skills and computational resources are required to narrow them down computationally.
The single mutant function prediction analysis service “digzyme in silico DMS (Deep Mutational Scanning)” for precision fermentation and in vitro diagnostic enzymes, which was recently released within the data analysis technology sharing platform “ANCAT,” makes it easy to predict the function of single mutants for precision fermentation and in vitro diagnostic enzymes. Since the analysis work is performed by the researchers themselves, it is relatively inexpensive compared to general contract analysis, and data analysis can be performed seamlessly in line with the progress of the research.
In order to overcome the current situation where there is a shortage of personnel capable of data analysis in the field, which causes research to stagnate and many laboratories and research teams to be troubled by the high cost of outsourcing analysis, Amplat has developed and operates a platform called “ANCAT” that allows researchers themselves to easily perform analysis even without specialized computing technology knowledge. This collaboration combines the advanced bioinformatics technology shared by both companies, and further combines Amplat‘s “power of generalization” using its high IT skills with digzyme‘s “expertise in enzyme discovery,” as one of the solutions to realize digzyme’s mission of “Let’s go and meet enzymes that will change the world.”
SOURCE: PRTimes
